The Department of Defense, through the United States Army Medical Research Acquisition Activity (USAMRAA), intends to negotiate a sole source contract with Helix Biotech for the acquisition of a Nova Benchtop Microfluidics device. This procurement aims to secure a chip-less, scalable, and highly flexible modular system essential for the encapsulation of mRNA for cellular delivery, including all necessary ancillary components, delivery, self-installation with virtual support, training, and a one-year manufacturer warranty. The device is critical for producing lipid nanoparticles, which play a significant role in various biomedical applications. Interested parties may submit their capability information by 2:00 p.m. Eastern Time on January 16, 2025, to Ms. Natalie Bethel at natalie.l.bethel2.civ@health.mil, as this notice is not a request for competitive quotations.